Skip to main content

International Journal of Phytomedicine and Phytotherapy

Table 2 Baseline characteristics of included patients (ITT analysis)

From: Efficacy and safety of Cineole (Soledum®) in the treatment of patients with acute bronchitis: results of an open-label randomized clinical phase III study

 

Cineole group

Standard group

overall

p-value

 

n = 65

n = 65

n = 130

 

Male

n = 25

n = 17

n = 42

 

Female

n = 40

n = 48

n = 88

 

Age (years, range)

44,4 (20–70)

43,7 (18–69)

 

0,7418

Weight (kg, range)

77,2 (51–120)

73,5 (48–104)

 

0,2980

Height (cm, range)

170,9 (156–196)

169,3 (155–190)

 

0,3553

BMI (range)

26,3 (19,2-38,2)

25,6 (17,9-36,0)

 

0,4775

Acute bronchitis

n = 31

n = 35

n = 66

 

Acute tracheobronchitis

n = 34

n = 28

n = 62

 

Acute tracheitis

n = 2

n = 2

 

BSS symptoms (range)

 Cough

2,9 (2–4)

3 (2–4)

 

0,3270

 Sputum

1,8 (0–4)

1,5 (0–3)

 

0,1270

 Chest pain

1,5 (0–3)

1,7 (0–3)

 

0,0784

 Wheezing

1,4 (0–2)

1,4 (0–3)

 

0,6293

 Dyspnea

0,8 (0–2)

1,0 (0–3)

 

0,2491

Total BSS Score

8,4 (5–14)

8,7 (5–14)

 

0,2937

Cough Frequency Likert Scale Score

5

5

  

Pretreatment NSAIDs

11

8

19

 

Pretreatment metamizole/paracetamol

2

5

7

 
  1. ITT Intention to treat, BSS Bronchitis Severity Scale, NSAID Non-steroidal anti-inflammatory drug)